CSPAX
Price
$80.84
Change
+$0.26 (+0.32%)
Updated
Sep 11 closing price
Net Assets
91.39B
LPFCX
Price
$4.40
Change
+$0.04 (+0.92%)
Updated
Sep 11 closing price
Net Assets
42.32M
Interact to see
Advertisement

CSPAX vs LPFCX

CSPAX vs LPFCX Comparison Chart in %
View a ticker or compare two or three
VS
CSPAX vs. LPFCX commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSPAX is a Buy and LPFCX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CSPAX has more cash in the bank: 91.4B vs. LPFCX (42.3M). LPFCX pays higher dividends than CSPAX: LPFCX (6.21) vs CSPAX (0.59). CSPAX was incepted earlier than LPFCX: CSPAX (25 years) vs LPFCX (16 years). LPFCX (2.71) is less costly to investors than CSPAX (1.04). CSPAX is a more actively managed with annual turnover of: 41.00 vs. LPFCX (31.00). CSPAX has a lower initial minimum investment than LPFCX: CSPAX (250) vs LPFCX (2500). CSPAX annual gain was more profitable for investors over the last year : 8.87 vs. LPFCX (-19.57). CSPAX return over 5 years is better than : -9.59 vs. LPFCX (-22.24).
CSPAXLPFCXCSPAX / LPFCX
Total Expense Ratio1.042.6240%
Annual Report Gross Expense Ratio1.042.7138%
Fund Existence25 years16 years-
Gain YTD12.262-6.237-197%
Front Load4%N/A-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets91.4B42.3M216,076%
Annual Yield % from dividends0.596.219%
Returns for 1 year8.87-19.57-45%
Returns for 3 years37.255.07735%
Returns for 5 years-9.59-22.2443%
Returns for 10 years82.3933.01250%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAZLX106.980.87
+0.82%
Oakmark Select R6
FCGEX21.230.15
+0.71%
NYLIM PineStone Global Equity Class A
FSTBX23.74N/A
N/A
Federated Hermes Global Allocation A
PCCEX11.50N/A
N/A
Franklin Dynamic Asset Allocation CnsvR6
VSENX48.14N/A
N/A
JPMorgan Small Cap Equity R6